Revenue: As of FY2026 Q1, the actual value is USD 4.712 M.EPS: As of FY2026 Q1, the actual value is USD -2.14.EBIT: As of FY2026 Q1, the actual value is USD -2.237 M.<h3>Segmented Financial Metrics</h3><h4>Fintech Segment</h4><ul><li>Revenue: $4,712 thousand for the 13 weeks ended March 28, 2026, a decrease of approximately $0.1 million from $4,849 thousand for the 13 weeks ended March 29, 2025.</li><li>Gross Profit: $3,574 thousand for the 13 weeks ended March 28, 2026, an increase of approximately $1.6 million from $1,926 thousand for the 13 weeks ended March 29, 2025.</li><li>Gross Margin Percentage: 75.9% for the 13 weeks ended March 28, 2026, up from 47.0% for the 13 weeks ended March 29, 2025.</li><li>Selling, General and Administrative (SG&amp;A) Expenses: $5,212 thousand for the 13 weeks ended March 28, 2026, compared to $2,604 thousand for the 13 weeks ended March 29, 2025.</li><li>Operating Loss: - $1,638 thousand for the 13 weeks ended March 28, 2026, compared to - $678 thousand for the 13 weeks ended March 29, 2025.</li><li>Depreciation and Amortization: $888 thousand for the 13 weeks ended March 28, 2026, compared to $728 thousand for the 13 weeks ended March 29, 2025.</li><li>Interest (expense) income, net: - $379 thousand for the 13 weeks ended March 28, 2026, compared to - $376 thousand for the 13 weeks ended March 29, 2025.</li><li>Net income (loss) before income taxes: $1,631 thousand for the 13 weeks ended March 28, 2026, compared to $543 thousand for the 13 weeks ended March 29, 2025.</li></ul><h4>Biotechnology Segment (Discontinued Operations)</h4><ul><li>Revenue: $0 for both the 13 weeks ended March 28, 2026, and March 29, 2025.</li><li>Gross Profit: $0 for both periods.</li><li>Selling, General and Administrative (SG&amp;A) Expenses: $177 thousand for the 13 weeks ended March 28, 2026, compared to $540 thousand for the 13 weeks ended March 29, 2025.</li><li>Operating Loss: - $177 thousand for the 13 weeks ended March 28, 2026, compared to - $540 thousand for the 13 weeks ended March 29, 2025.</li><li>Depreciation and Amortization: $0 for the 13 weeks ended March 28, 2026, compared to $482 thousand for the 13 weeks ended March 29, 2025.</li><li>Interest (expense) income, net: $0 for both periods.</li><li>Net income (loss) before income taxes: - $177 thousand for the 13 weeks ended March 28, 2026, compared to - $540 thousand for the 13 weeks ended March 29, 2025.</li></ul><h4>Corporate and Other Segment</h4><ul><li>Revenue: $0 for both periods.</li><li>Gross Profit: $0 for both periods.</li><li>Selling, General and Administrative (SG&amp;A) Expenses: $1,105 thousand for the 13 weeks ended March 28, 2026, compared to $1,268 thousand for the 13 weeks ended March 29, 2025.</li><li>Operating Loss: - $1,105 thousand for the 13 weeks ended March 28, 2026, compared to - $1,268 thousand for the 13 weeks ended March 29, 2025.</li><li>Depreciation and Amortization: $0 for both periods.</li><li>Interest (expense) income, net: - $127 thousand for the 13 weeks ended March 28, 2026, compared to - $344 thousand for the 13 weeks ended March 29, 2025.</li><li>Net income (loss) before income taxes: - $358,028 thousand for the 13 weeks ended March 28, 2026, compared to - $1,690 thousand for the 13 weeks ended March 29, 2025.</li></ul><h4>Company-Wide Financial Metrics</h4><ul><li>Net Loss from Continuing Operations: - $271,316 thousand for the 13 weeks ended March 28, 2026, compared to - $1,912 thousand for the 13 weeks ended March 29, 2025.</li><li>Net Loss: - $271,493 thousand for the 13 weeks ended March 28, 2026, compared to - $2,392 thousand for the 13 weeks ended March 29, 2025.</li><li>Unrealized Loss on Cryptocurrency Assets: - $348,301 thousand for the 13 weeks ended March 28, 2026, compared to $0 for the same period in the prior year.</li><li>Realized (Loss) Gain on Exchange Transactions: - $6,082 thousand for the 13 weeks ended March 28, 2026, compared to $973 thousand for the same period in the prior year.</li><li>Operating Cash Flows: Cash used in operations was approximately - $12.3 million for the 13 weeks ended March 28, 2026, compared to cash provided by operations of approximately $1.5 million for the 13 weeks ended March 29, 2025.</li><li>Investing Cash Flows: Cash provided by investing activities was $0 for both periods.</li><li>Financing Cash Flows: Cash provided by financing activities was $8.5 million for the 13 weeks ended March 28, 2026, primarily due to the new WLFI loan, compared to $1.5 million for the 13 weeks ended March 29, 2025.</li><li>Cash and Cash Equivalents, end of period: $10,522 thousand as of March 28, 2026, compared to $10,931 thousand as of March 29, 2025.</li><li>Working Capital: As of March 28, 2026, AI Financial Corporation had a working capital deficit of approximately - $5.5 million, with total current liabilities of $39.1 million against total current assets of $32.2 million.</li></ul><h3>Unique Metrics</h3><ul><li>WLFI Token Holdings: AI Financial Corporation holds approximately 7.3 billion WLFI tokens, carried at a fair value of approximately $703.4 million as of March 28, 2026. These tokens were acquired through a treasury program initiated on August 12, 2025, totaling 7,283,585,650 WLFI tokens at $0.20 per token.</li></ul><h3>Future Outlook and Strategy</h3>AI Financial Corporation’s strategy involves managing liquidity, achieving revenue growth in its Fintech segment, and potentially raising additional capital through debt or equity financing. The company maintains a long-term “HODL” approach for its WLFI tokens, with future acquisitions funded by operating cash flows, structured debt, and selective capital raises, while sales are restricted to liquidity needs or material portfolio rebalancing. Furthermore, the company plans to capitalize a subsidiary with biotechnology assets, acquire an additional biotechnology asset, and secure financing for that subsidiary to operate independently while retaining a controlling interest.

AI Financial | 10-Q: FY2026 Q1 Revenue: USD 4.712 M